280 related articles for article (PubMed ID: 27603551)
21. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
23. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
Jacobsoone-Ulrich A; Jamme P; Alkeraye S; Dzwiniel V; Faure E; Templier C; Mortier L
Melanoma Res; 2016 Apr; 26(2):153-6. PubMed ID: 26636908
[TBL] [Abstract][Full Text] [Related]
24. Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.
Zehou O; Leibler C; Arnault JP; Sayegh J; Montaudié H; Rémy P; Glotz D; Cordonnier C; Martin L; Lebbé C
Am J Transplant; 2018 Dec; 18(12):3065-3071. PubMed ID: 30107088
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
[TBL] [Abstract][Full Text] [Related]
26. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
28. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.
Lee B; Wong A; Kee D; Neeson P; Shackleton M; McArthur G; Sandhu S
Ann Oncol; 2016 Jun; 27(6):1174-1177. PubMed ID: 26861600
[No Abstract] [Full Text] [Related]
29. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Aamdal E; Jacobsen KD; Straume O; Kersten C; Herlofsen O; Karlsen J; Hussain I; Amundsen A; Dalhaug A; Nyakas M; Schuster C; Hagene KT; Holmsen K; Russnes HG; Skovlund E; Kaasa S; Aamdal S; Kyte JA; Guren TK
Int J Cancer; 2022 Jan; 150(1):100-111. PubMed ID: 34449877
[TBL] [Abstract][Full Text] [Related]
31. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
32. Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
Plaquevent M; Greliak A; Pinard C; Duval-Modeste AB; Joly P
Melanoma Res; 2019 Jun; 29(3):311-312. PubMed ID: 31026247
[TBL] [Abstract][Full Text] [Related]
33. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma.
Li M; Basu A; Bennette C; Veenstra D; Garrison LP
Value Health; 2019 Jul; 22(7):777-784. PubMed ID: 31277824
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.
Kähler KC; Eigentler TK; Gesierich A; Heinzerling L; Loquai C; Meier F; Meiss F; Pföhler C; Schlaak M; Terheyden P; Thoms KM; Ziemer M; Zimmer L; Gutzmer R;
Cancer Immunol Immunother; 2018 May; 67(5):825-834. PubMed ID: 29487980
[TBL] [Abstract][Full Text] [Related]
35. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
36. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review.
Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE
Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307
[TBL] [Abstract][Full Text] [Related]
37. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
Daly LE; Power DG; O'Reilly Á; Donnellan P; Cushen SJ; O'Sullivan K; Twomey M; Woodlock DP; Redmond HP; Ryan AM
Br J Cancer; 2017 Jan; 116(3):310-317. PubMed ID: 28072766
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.
Arzu Yaşar H; Turna H; Esin E; Murat Sedef A; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akbulut H; Celik I; Abalı H; Urun Y
J Oncol Pharm Pract; 2020 Mar; 26(2):267-272. PubMed ID: 30924738
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
